Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ICCM
Upturn stock ratingUpturn stock rating

Icecure Medical (ICCM)

Upturn stock ratingUpturn stock rating
$1
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ICCM (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $3.01

1 Year Target Price $3.01

Analysts Price Target For last 52 week
$3.01Target price
Low$0.48
Current$1
high$1.66

Analysis of Past Performance

Type Stock
Historic Profit -29.59%
Avg. Invested days 36
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 59.28M USD
Price to earnings Ratio -
1Y Target Price 3.01
Price to earnings Ratio -
1Y Target Price 3.01
Volume (30-day avg) 3
Beta 2.59
52 Weeks Range 0.48 - 1.66
Updated Date 06/29/2025
52 Weeks Range 0.48 - 1.66
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.28

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -504.41%

Management Effectiveness

Return on Assets (TTM) -72.28%
Return on Equity (TTM) -173.48%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 53538191
Price to Sales(TTM) 18.11
Enterprise Value 53538191
Price to Sales(TTM) 18.11
Enterprise Value to Revenue 16.36
Enterprise Value to EBITDA -2.63
Shares Outstanding 58693400
Shares Floating 30741892
Shares Outstanding 58693400
Shares Floating 30741892
Percent Insiders 47.55
Percent Institutions 0.22

Analyst Ratings

Rating 2
Target Price 3.01
Buy 2
Strong Buy 1
Buy 2
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Icecure Medical

stock logo

Company Overview

overview logo History and Background

IceCure Medical Ltd. was founded in 2006 and is an Israeli medical device company focused on developing and commercializing minimally invasive cryoablation technology for the treatment of tumors. It has evolved from initial research and development to clinical trials and commercial product launches.

business area logo Core Business Areas

  • Cryoablation Systems: Development, manufacturing, and marketing of cryoablation systems, primarily the ProSense system, for tumor ablation.
  • Single-Use Consumables: Sale of single-use cryoprobes and related consumables used with the ProSense system.

leadership logo Leadership and Structure

The leadership team typically includes a CEO, CFO, and heads of research & development, operations, and sales & marketing. The organizational structure is typical of a medical device company, with departments focused on research, manufacturing, regulatory affairs, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • ProSense System: The ProSense system is IceCure's primary product, used for cryoablation of benign and malignant tumors, particularly in breast, kidney, and lung. Specific market share data is challenging to obtain and highly variable by indication. Competitors include Medtronic (MDT) and Boston Scientific (BSX) in the broader ablation market. Revenue figures are usually detailed in annual reports.

Market Dynamics

industry overview logo Industry Overview

The medical device industry is highly competitive and innovative, with increasing demand for minimally invasive procedures. The cryoablation market is growing, driven by the benefits of reduced recovery time and fewer complications compared to traditional surgery.

Positioning

IceCure Medical is positioned as a specialist in cryoablation technology, focusing on specific tumor types and offering a minimally invasive alternative to surgery. Their competitive advantage lies in the simplicity and effectiveness of the ProSense system.

Total Addressable Market (TAM)

The total addressable market for cryoablation is estimated to be in the hundreds of millions of dollars annually and is expanding. IceCure is positioned to capture a portion of this TAM through continued commercialization efforts and expansion into new indications.

Upturn SWOT Analysis

Strengths

  • Minimally invasive technology
  • Effective tumor ablation
  • Established regulatory approvals
  • Targeted approach in specific tumor types

Weaknesses

  • Limited financial resources
  • Small commercial team
  • Reliance on a single primary product
  • Requires more clinical trial validation in additional indications

Opportunities

  • Expansion into new tumor types and indications
  • Partnerships with larger medical device companies
  • Increasing adoption of minimally invasive procedures
  • Geographic expansion into new markets

Threats

  • Competition from established medical device companies
  • Technological advancements in alternative ablation techniques
  • Regulatory hurdles and changes in reimbursement policies
  • Economic downturn affecting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • MDT
  • BSX
  • CRYO

Competitive Landscape

IceCure Medical faces competition from larger, established medical device companies with broader product portfolios. IceCure's advantage lies in its specialized cryoablation technology, while its disadvantage is its smaller size and limited resources.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by increasing revenue as the ProSense system gains adoption. However, growth is variable and dependent on regulatory approvals and market penetration.

Future Projections: Future growth projections depend on successful commercialization efforts, expansion into new indications, and potential partnerships. Analyst estimates may vary.

Recent Initiatives: Recent initiatives include pursuing regulatory approvals for new indications, expanding the commercial team, and conducting clinical trials to support broader adoption of the ProSense system.

Summary

IceCure Medical is a small medical device company focused on cryoablation technology that has developed an effective product. IceCure has regulatory approvals and is expanding its commercial presence. Its small size and limited resources are weaknesses, and it needs to be mindful of its larger competitors and regulatory changes. Continued clinical validation and market adoption are important to the future success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • IceCure Medical's website
  • SEC filings (10-K, 10-Q)
  • Press releases
  • Analyst reports

Disclaimers:

This analysis is based on available information and is not financial advice. Market share data is approximate and may vary. Please consult with a financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Icecure Medical

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-08-26
CEO & Director Mr. Eyal Shamir
Sector Healthcare
Industry Medical Devices
Full time employees 64
Full time employees 64

IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.